On this page you’ll find the latest news about CATALONIA.HEALTH and the member companies and knowledge stakeholders in the field of health and life sciences.
If you want to receive our news, please sign up for the monthly newsletter on our website or follow us on X and LinkedIn with the hashtag #WeAreCataloniaHealth.
22 October 2020
Ability Pharma, a CataloniaBio & HealthTech member focused on the development of innovative oral anticancer compounds, has received a €1.6 million grant from the Food and Drug Administration (FDA).
This year the biopharmaceutical company based at the UAB Research Park expects to raise a total of €9.2 million to fund clinical phase IIb of the ABTL0812 treatment for pancreatic cancer. ABTL0812 has obtained positive results in clinical trial in patients with endometrial and lung cancer.
Last March, Ability received €5 million from the European Innovation Council (EIC). The remaining €2.6 million will come through ...
22 October 2020
Chemotargets, a CataloniaBio & HealhTech member, has appointed Scott Boyer as new CEO with the aim to consolidate its business transition from a software business to a biotechnology company.
Boyer has a PhD in Molecular Toxicology from the University of Colorado (US). He joins Chemotargets from Swedish pharmaceutical company Klaria. Prior he was CSO at AstraZeneca in Sweden and senior scientist at Pfizer Central Research in the US.
Boyer’s short-term goals include closing the Series A funding round opened in July.
Genesis Biomed is advising Chemotargets in the transformation of the company.
Photo: Scott Boyer - © Chemotargets ...
21 October 2020
The Spanish Society of Periodontology and Osseointegration (SEPA) and Dentaid, a CataloniaBio & HealthTech member, hosted the fifth annual scientific dentistry symposium on 3 October, connecting over 6,000 professionals online.
The symposium dealt with preventing and restoring oral health for good overall health. 11.2% of the global population has advanced periodontitis, a gum infection that can lead to tooth loss and systemic diseases like diabetes and cardiovascular conditions.
Participants also discussed how SARS-CoV-2 interacts in the oral cavity, protection and work methods for dentists, and evidence supporting the role antiseptics play in preventing viral infections, especially Cetylpyridinium chloride ...
16 October 2020
Best of the 2020 CataloniaBio & HealthTech Gala:
2020 is a year for the history books. Covid-19 is having affecting our whole society and posing challenges we have to face together. As could be no other way, the pandemic also marked the sixth annual CataloniaBio & HealthTech Gala, the yearly gathering of the Catalan healthcare and life sciences sector, held this year online from Gaudí’s Crypt at Colonia Güell. More than 180 entrepreneurs, executives and investors followed the event on screen.
The CataloniaBio & HealthTech Board of Directors highlighted the indicators* confirming the sector is in a good place ...
15 October 2020
CataloniaBio & HealthTech presented the 2020 Biosuccess Award to Kymos for its consolidation, international expansion and key role in dynamising the healthcare and life sciences sector in Catalonia as a science services company.
The awards ceremony took place yesterday during the CataloniaBio & HealthTech Gala, which this year was streamed online from the Gaudi’s Crypt in Colonia Güell and held during the day due to the Covid-19 situation. The sector’s main yearly event featured Secretary of Economy of the Government of Catalonia Natàlia Mas, Director General for Research and Innovation in Health Robert Fabregat, and the CataloniaBio & HealthTech ...
11 October 2020
FreeOx Biotech, a CataloniaBio & HealthTech member, has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use of Ox-01 until 2038 for patients with ischaemic stroke treated with mechanical thrombectomy.
“This grant is wonderful news for the company as it will allow us to strengthen our drug’s protection in a market representing approximately 50% worldwide in terms of returns and move forward with our regulatory plan with close communication with EMA” said Carlos Lurigados, co-founder and CEO of FreeOx.
Ox-01 is currently in clinical phase ...
7 October 2020
Maria Fátima Lucas, co-founder and CEO of the Barcelona-based start-up Zymvol Biomodeling, is one of the four winners of 2020 EU Prize for Women Innovators. She will receive a €100,000 cash prize.
During the European Research and Innovation Days on 24 September, commissioner for Innovation and Research Mariya Gabriel revealed the winners chosen by a jury of independent experts.
The other recognised women are Madiha Derouazi, founder and CEO of Amal Therapeutics (Switzerland), Arancha Martínez, co-founder and managing director of It Will Be (Spain) and Josefien Groot, co-founder and CEO of Qlayers (Netherlands).
Zymvol Biomodeling was founded in ...
7 October 2020
Two active ingredients from Vytrus Biotech, a CataloniaBio & HealthTech member, have been recognised with the 2020 Best Ingredient Award, given out annually at the top international cosmetics fair: In-Cosmetics Global. The ceremony was streamed live online on 6 October.
These awards recognise innovation in raw materials in the cosmetics industry. From Vytrus, the winning ingredients are Kannabia Sense and Deobime Noni, for their science, mechanisms of action and the market need they address.
You may also be interested in:
Vytrus Biotech launches the first biological deodorant of the marketVytrus Biotech celebrates 10th anniversary with eyes on ...7 October 2020
Inveready, a venture capital management firm and CataloniaBio & HealthTech member, has closed its first vehicle, Inveready Seed Capital SCR, after 11 years with returns of €100 million.
Inveready Seed Capital was created to invest in early-stage technology companies and, in total, the fund has participated in 35 firms, 40% in the healthcare and life sciences sector. The life sciences portfolio out-performed investment five-fold.
“We are very pleased with the return on this fund, one of the sector's most successful in Europe, as well as its social and economic impact,” notes Inveready President Josep Maria Echarri.
The fund ...
1 October 2020
Kymos Pharma, a Contract Research Organisation (CRO) and member of CataloniaBio & HealthTech, has bought German company Prolytic GmbH in order to strengthen its activity in the biologics and advanced therapies market. The company previously acquired Italian firm Pharmaprogress in 2016.
"This strategic merger gives us the opportunity to increase our service offering, strengthen the emerging therapies market and create a multinational and multidisciplinary company. We are very much looking forward to this new phase in the company’s history", says Joan Puig de Dou, co-founder and CEO of Kymos Pharma.
From now on, Kymos' services will be for innovative small and ...
28 September 2020
Aortyx, spin-off of the IQS School of Engineering, has won the first annual Àlex Casta Awards for best pitch in the healthcare and life sciences ecosystem in Catalonia. The competition took place today at the presentation of the 2020 BioRegion of Catalonia Report, compiled by Biocat and CataloniaBio & HealthTech.
The other start-ups that competed as finalists were Ona Therapeutics, Glycardial Diagnostics, Able Human Motion and Pebble Analytics.
Founded by Jordi Martorell, Salvador Borrós and Vicenç Riambau, head of Vascular Surgery at Hospital Clinic Barcelona, Aortyx is developing a new generation of grafts to repair blood vessels.
“I hope these ...
28 September 2020
With three months until the end of 2020, the life sciences and healthcare sector in Catalonia is flexing its muscles, in spite of expectations it would be a challenging year due to the Covid-19 pandemic. Start-ups in this ecosystem, the most dynamic in Spain and one of the most active in southern Europe, have managed to raise €120 million in investment, well above the previous record from 2019, which was €112 million. This data is from the BioRegion of Catalonia Life Sciences and Healthcare Outlook 2020 - Challenges Ahead, the report presented today by Biocat and CataloniaBio & HealthTech.
President ...
25 September 2020
Minoryx Therapeutics, a CataloniaBio & HealthTech member, and Sperogenix Therapeutics entered into an exclusive license agreement for the development and commercialization of MIN-102 for the treatment of X-linked adrenoleukodystrophy (X-ALD) in China, Hong Kong and Macau. Currently, there is no treatment for X-ALD.
Under the terms of the agreement, Minoryx will receive an initial upfront payment and pre-defined regulatory and commercial milestone payments of up to €66-million, as well as double-digit royalties on annual net sales.
Marc Martinell, co-founder and CEO of Minoryx, says that "Sperogenix is a company with experience and capabilities in the field of rare diseases in ...
23 September 2020
Josep Amat, co-founder and CSO of Rob Surgical, received the Creu de Sant Jordi 2020 from the Government of Catalonia for his extensive background as a robotics engineer.
Amat is co-inventor of the new Bitrack robot for minimally invasive surgery, and the first entrepreneur from CataloniaBio & HealthTech to receive this recognition.
Currently, he is emeritus professor of architecture and computer science at the Polytechnic University of Catalonia (UPC), advisor to the Robotics and Vision Group at the Research Centre for Biomedical Engineering-UPC and member of the Institute for Catalan Studies (IEC).
The awards ceremony took place on 21 September ...
23 September 2020
Asabys Partners, a venture capital firm and member of CataloniaBio & HealthTech, has participated in Medasense Biometrics Ltd’s €15.2-million Series C round of funding along with investors such as Baxter and Olive Tree Ventures, among others.
Medasense was founded in Tel Aviv in 2008 by Galit Zuckerman and has offices in Barcelona and Berlin.
The company has developed sensor technology based on artificial intelligence (PMD-200) to monitor the pain of sedated patients and optimise the administration of anaesthesia, in critical-care and operating-room settings where patients are unable to communicate. Currently, the company is active in implementing its technology for ...
17 September 2020
ProteoDesign, founded in 2012 and CataloniaBio & HealthTech member, rebrands as Splice Bio to develop novel gene therapies throught its proprietary platform based on technology developed in the Muir Lab at Princeton University.
The Barcelona-based biotech company also announces a new investment led by Ysios Capital and joined by Asabys Partners. This financing round was organised thanks to the support of existing shareholder Caixa Capital Risc.
Splice Bio pioneering platform has the potential to target genetic diseases that cannot be addressed with current gene therapies. Specifically, it has the potential to address two existing limitations of adeno-associated ...
10 September 2020
The founders of WIVI Vision, Eva García Ramos and Juan Carlos Ondategui-Parra, have made the Forbes Spain Top 100 most creative business people in Spain.
WIVI Vision is a medical solution that assesses children’s visual issues and offers early diagnosis and more advanced treatment than current ophthalmologic and optometry solutions. Specifically, WIVI uses immersive 3D software and a visual training plan personalised to each patient.
In Europe alone, there are over 15 million children with vision problems that are often confused with dyslexia and hyperactivity.
Eva García Ramos and Juan Carlos Ondategui-Parra founded the start-up E-Health Technical Solutions ...
9 September 2020
Methinks, a digital health start-up and CataloniaBio & HealthTech member, has raised €1.2 million in a round led by Nina Capital, along with other investors and business angels from the Capital Cell platform.
Methinks has developed medical imaging software that detects cerebral artery occlusions and haemorrhages using artificial intelligence (AI) without the need for a CT scan with contrast. The company’s disruptive technology is currently being developed at Barcelona’s Vall d’Hebron University Hospital. This round of investment will allow it to launch the product to market and secure licensing deals.
Using AI to interpret medical images is ...
8 September 2020
The University of Barcelona (UB) and medical technology company Avinent have expanded their collaboration by launching a new chair to address the needs of the oral implantology sector
The chair will promote preclinical and clinical research and training through activities in the Faculty of Medicine and Health Sciences. A UB-Avinent Chair award will also be set up to foster clinical excellence in oral implantology.
Led by Albert Giralt, a CataloniaBio & HealthTech board member, Avinent is a global benchmark in latest generation dental implants and is present on all continents. The company works with dentists, prosthesis experts and maxillofacial ...
8 September 2020
IOMED, a digital health start-up and CataloniaBio & HealthTech member, has closed a €2-million investment round led by Adara Ventures. Existing investors in the company, such as Easo Ventures and Speedinvest, have also taken part.
The operation has had the legal support of the law firm DWF-RCD.
“This round’s goal is to strongly expand our team and continue the expansion in Spanish hospitals as well as to undertake more activities abroad with a particular focus on Germany and the United Kingdom,” explains Javier de Oca, co-founder and CEO of IOMED.
IOMED’s technology, based on artificial intelligence and natural ...